CompanyPTCTNasdaqWarren, NJ

PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company developing medicines for rare disorders in children and adults.

SEC EDGAR ClinicalTrials.gov ptcbio.com

8-KSep 21Latest SEC filing, period to Sep 21

Sep 21Latest story

September 2026

PTC Therapeutics closes acquisition of Sangamo's ST-920 Fabry gene therapy

Sep 21M&APTC Therapeutics

August 2026

PTC Therapeutics details terms of Sangamo gene therapy asset deal

Aug 28PartnershipPTC Therapeutics

PTC Therapeutics registers Phase 2A trial of PTC844 in rheumatoid arthritis

Aug 21Trial updatePTC Therapeutics PTC844

PTC Therapeutics wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920

Aug 13M&APTC Therapeutics

July 2026

PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidance

Jul 30Quarterly updatePTC Therapeutics sepiapterin

PTC Therapeutics registers Phase 3 PROVE-FA trial for vatiquinone in Friedreich's Ataxia

Jul 2Trial updatePTC Therapeutics vatiquinone